Cankado

01/10/2021

Do not miss our Poster presentation at
2021 Congress,
On AI-based Smartphone APP for QTc diagnostics using a single-lead ECG for oncological routine.
Our Project Manager Lena is the presenter of the poster.

22/09/2021

Upcoming Event - Poster Presentation At 2021
On AI-based Smartphone APP for QTc diagnostics using a single-lead ECG for oncological routine
by our Project Manager Lena-Sophie Fink

01/07/2021

Launching today - ‘Colloquium Senologie 2021/2022’, a book series on practice-changing developments in therapy.
is proud to have contributed to the Chapter, ‘Digital Health Applications’ , in the upcoming edition of Colloquium Senologie.

Launch event programme details,
When - Today , 1st July 2021, between 17:00 hrs - 19:30 hrs
Where - In Online event programme, ‘Colloquium Senologie 2021/2022’ (www.colloquium-senologie.de)


https://presseportal.org/cankado-contributes-to-colloquium-senology-2021-2022/

A book series on practice-changing developments in breast cancer therapy Cologne, Germany, 01.07.2021 - The book series, 'Colloquium Senologie' targets

25/06/2021

CANKADO co-authors in ‘Colloquium Senologie 2021/2022’. This is a book series aimed at all doctors who are dedicated to the care of breast cancer patients.
Prof. Dr. Timo Schinköthe, CEO, CANKADO has contributed to the chapter, ‘Digital Health Applications’, in the upcoming edition of Colloquium Senologie.
The launching of the book scheduled on 1st July 2021 in an online event program, 'Colloquium Senologie 2021/2022'.

When: 01 July 2021 between 17:00 hr - 19:00 hr
Where: Online event program, colloquium Senologie 2021/2022 (https://colloquium-senologie.de/)

27/05/2021

Know more on PRO-React Onco, First ‘App on Prescription’ for Breast Cancer Treatment Support.
PRO-React Onco can now be prescribed as DiGA in Germany to accompany the treatment of breast cancer patients.

Germany's first DiGA for Breast Cancer Patients 'PRO-React Onco’ from CANKADO Now Approved as a Digital Health Application (DiGA)  Share on linkedin Share on twitter Share on facebook Share on whatsapp Cologne, Germany, 26.05.2021 - CANKADO’s digital health application (Digitale Gesundheitsanwe...

04/05/2021

CANKADO PRO-React Onco developed by CANKADO Service GmbH is approved as a (Digital Health Application) by Federal Institute for Drugs and Medical Devices ( BfArM ) and has been added to the DiGA directory.

CANKADO PRO-React Onco supports breast cancer patients in their treatment journey as a comprehensive digital therapy companion. The application is now available as 'App on Prescription'.
We thank all our team members across the globe for their effort and great dedication which lead to the achievement of this significant milestone.
https://diga.bfarm.de/de/verzeichnis/961

22/03/2021

CANKADO is pleased to announce that the tele-cardiology application, QTc Tracker and its striking results and the substantial workflow presented in the digital poster at Quality of Cancer Care (QoCC) 2021 won one of the three poster prizes of the congress QoCC 2021.

The presentation was held on 9th February 2021 and was presented by CANKADO’s project manager Lena-Sophie Fink.

https://partners.cankado.com/cankados-digital-poster-presentation-won-one-of-the-three-poster-prizes-of-qocc-2021/

CANKADO’s Tele-Cardiology Application Won the QoCC 2021 Poster Prize The striking results and the substantial workflow of the tele-cardiology application, QTc Tracker received the prize The digital poster presented by CANKADO together with Ludwig Maximilian University of Munich (LMU), West German ...

08/02/2021

CANKADO together with Ludwig Maximilian University of Munich, West German Study Group and Kliniken Essen-Mitte GmbH is to present a digital poster at the virtual congress, ‘Quality of Cancer Care’ (QoCC) 2021.

The poster is based on the findings that CANKADO’s tele-cardiology application, QTc tracker has enabled up to 99% reduction in turnaround time for QTc diagnosis.

CANKADO’s project manager Lena-Sophie Fink will present the poster on 9th February.

CANKADO’s Tele-Cardiology Application, QTc Tracker Enabled to Achieve Upto 99% Reduction in Turnaround Time for QTc Diagnosis CANKADO’s project manager Lena-Sophie Fink will present the digital poster at QoCC 2021 on 9th February CANKADO together with Ludwig Maximilian University of Munich, West...

22/01/2021

CANKADO is delighted to announce that we have contributed to the book ‘Innovationsfonds – Transfer in die Regelversorgung’ which has been recently published.
CANKADO’s CEO Prof. Dr. Timo Schinköthe and project manager Lena-Sophie Fink contributed a description of innovation funding of digital health applications from an entrepreneur perspective.
The book focuses on interim assessment, best practice examples and recommendations for actions to promote and implement innovations in the German healthcare system.

CANKADO’s CEO Prof. Dr. Timo Schinköthe and project manager Lena-Sophie Fink have contributed to the book titled, ‘Innovationsfonds – Transfer in die Regelversorgung’ Share on linkedin Share on twitter Share on facebook Share on whatsapp The book, ‘Innovationsfonds-Transfer in die Regelve...

08/01/2021

The new clinical trial, ADAPTlate conducted by West German Study Group enrolled its first patients who are using the CANKADO system as part of the study to monitor their Quality of Life (QoL).

This oncologic clinical trial evaluates the efficacy and safety of the CDK 4/6 Inhibitor Abemaciclib in combination with endocrine therapy in high-risk

19/12/2020

CANKADO Companion-APP is a drug-tailored extension for comprehensive . The solution provides drug-optimized digital applications for .

CANKADO’s Companion-APP Solution provides Drug-Optimised Digital Applications for Pharmaceutical Companies The tool is a drug tailored extension of CANKADO’s e-Health solution Share on linkedin Share on twitter Share on facebook Share on whatsapp Cologne, Germany, 17.12.2020 - CANKADO’s Compan...

12/12/2020

Together with WSG(West German Study Group), has developed the EnRep tool to predict the probability of response to in early-stage patients.

EnReP has been introduced today at the (San Antonio Breast Cancer Symposium)

WSG and CANKADO's EnReP predict the benefits of anti-hormone therapy in breast cancer patients The tool developed on the basis of the ADAPT study data will be presented today at SABCS 2020. Share on linkedin Share on twitter Share on facebook Share on whatsapp Cologne, Germany, 11.12.2020 - The EnRe...